MEA Travel Vaccine Market - Industry Trends and Forecast to 2034

Description

List of Tables

Middle East and Africa travel vaccine market is expected to reach USD 1,210,595.40 thousand by 2032 from USD 646,979.92 thousand in 2023, growing at a substantial CAGR of 7.4% in the forecast period of 2024 to 2032.

Market Segmentation:

Middle East and Africa travel vaccines market, By Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric and Geriatric), Age Group (20-50 Years, Less than 20 Years and Above 50 Years), Distribution Channel (B2B and B2C), Countries (Saudi Arabia, U.A.E., Israel, South Africa, Egypt, Kuwait, and Rest of Middle East and Africa) , Industry Trends and Forecast to 2032

Some of the major factors contributing to the growth of the Middle East and Africa travel vaccines market are:

Driver
Rising incidence of infectious diseases
Restraint
High cost of travel vaccines
Opportunity
Advancements in vaccine technology

Market Players

Some major companies dealing in the Middle East and Africa travel vaccines market are:

GSK plc.
Pfizer Inc.
Abbott
CSL
AstraZeneca
Sanofi
Merck & Co., Inc.
Johnson & Johnson Services Inc.
Dynavax Technologies.

1 INTRODUCTION 49

1.1 OBJECTIVES OF THE STUDY 49
1.2 MARKET DEFINITION 49
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET 49
1.4 LIMITATIONS 51
1.5 MARKETS COVERED 51

2 MARKET SEGMENTATION 55

2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 CURRENCY AND PRICING 57
2.5 DBMR TRIPOD DATA VALIDATION MODEL 58
2.6 MULTIVARIATE MODELLING 61
2.7 PRODUCT TYPE LIFELINE CURVE 61
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
2.9 DBMR MARKET POSITION GRID 63
2.10 MARKET APPLICATION COVERAGE GRID 64
2.11 VENDOR SHARE ANALYSIS 65
2.12 SECONDARY SOURCES 66
2.13 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 70

4.1 PESTEL ANALYSIS 71
4.2 PORTER'S FIVE FORCES 72
4.3 PIPELINE ANALYSIS 73

5 MARKET OVERVIEW 77

5.1 DRIVERS 79
- 5.1.1 RISING INCIDENCE OF INFECTIOUS DISEASES 79
- 5.1.2 INCREASING TRAVEL AND TOURISM 81
- 5.1.3 GOVERNMENT REGULATIONS AND RECOMMENDATIONS REGARDING VACCINATION 82
- 5.1.4 EXPANSION OF TRAVEL MEDICINE CLINICS 82
5.2 RESTRAINTS 83
- 5.2.1 HIGH COST OF TRAVEL VACCINES 83
- 5.2.2 REGULATORY HURDLES FOR APPROVAL 84
5.3 OPPORTUNITIES 84
- 5.3.1 ADVANCEMENTS IN VACCINE TECHNOLOGY 84
- 5.3.2 GROWING AWARENESS REGARDING VACCINES 85
- 5.3.3 INTEGRATION OF DIGITAL HEALTH SOLUTIONS 85
5.4 CHALLENGES 86
- 5.4.1 COLD CHAIN REQUIREMENTS FOR STORAGE 86
- 5.4.2 VACCINE HESITANCY AND MISINFORMATION 87

6 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION 88

6.1 OVERVIEW 89
6.2 COMBINATION VACCINES 92
6.3 MONO VACCINES 92

7 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY TYPE 93

7.1 OVERVIEW 94
7.2 INACTIVATED VACCINES 97
- 7.2.1 HEPATITIS A 98
- 7.2.2 INFLUENZA 98
- 7.2.3 RABIES 98
- 7.2.4 TICK-BORNE ENCEPHALITIS 98
- 7.2.5 JAPANESE ENCEPHALITIS 98
- 7.2.6 POLIO 99
7.3 SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES 99
- 7.3.1 HEPATITIS B 100
- 7.3.2 MENINGOCOCCAL 100
- 7.3.3 MALARIA 100
- 7.3.4 COVID-19 100
7.4 LIVE-ATTENUATED VACCINES 101
- 7.4.1 TYPHOID 102
- 7.4.2 CHOLERA 102
- 7.4.3 YELLOW FEVER 102
- 7.4.4 MEASLES 102
- 7.4.5 MUMPS 103
- 7.4.6 RUBELLA 103
- 7.4.7 VARICELLA 103
- 7.4.8 OTHERS 103
7.5 TOXOID VACCINES 103
- 7.5.1 DIPHTHERIA 104
- 7.5.2 TETANUS 104
7.6 DNA VACCINES 104
7.7 VIRAL VECTOR VACCINES 105

8 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY CATEGORY 106

8.1 OVERVIEW 107
8.2 RECOMMENDED VACCINE 110
- 8.2.1 TYPHOID FEVER VACCINES 111
- 8.2.2 HEPATITIS A 111
- 8.2.3 CHOLERA 111
- 8.2.4 RABIES 111
- 8.2.5 TICK-BORNE ENCEPHALITIS 111
- 8.2.6 JAPANESE ENCEPHALITIS 111
- 8.2.7 MALARIA 111
- 8.2.8 OTHERS 111
8.3 ROUTINE VACCINE 112
- 8.3.1 HEPATITIS B 113
- 8.3.2 INFLUENZA VACCINES 113
- 8.3.3 PNEUMOCOCCAL 113
- 8.3.4 DIPHTHERIA 113
- 8.3.5 TETANUS 113
- 8.3.6 MEASLES 113
- 8.3.7 MUMPS 113
- 8.3.8 RUBELLA 113
- 8.3.9 PERTUSSIS 113
- 8.3.10 OTHERS 114
8.4 REQUIRED VACCINE 114
- 8.4.1 YELLOW FEVER 115
- 8.4.2 MENINGOCOCCAL 115
- 8.4.3 POLIO VACCINES 115

9 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISEASE 116

9.1 OVERVIEW 117
9.2 TYPHOID 121
9.3 HEPATITIS 121
- 9.3.1 HEPATITIS A 122
- 9.3.2 HEPATITIS B 122
9.4 CHOLERA 122
9.5 VARICELLA 123
9.6 INFLUENZA 123
9.7 JAPANESE ENCEPHALITIS 124
9.8 MENINGOCOCCAL MENINGITIS 124
9.9 YELLOW FEVER 125
9.10 RABIES 125
9.11 DPT 126
9.12 MEASLES AND MUMPS 126
9.13 TICK-BORNE ENCEPHALITIS 127
9.14 MALARIA 127
9.15 COVID-19 128
9.16 POLIO 128
9.17 OTHERS 129

10 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION 130

10.1 OVERVIEW 131
10.2 INJECTABLE 134
- 10.2.1 INTRAMUSCULAR 135
- 10.2.2 SUBCUTANEOUS 135
- 10.2.3 OTHERS 135
10.3 ORAL 135

11 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY GENDER 136

11.1 OVERVIEW 137
11.2 MALE 140
11.3 FEMALE 140

12 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE 141

12.1 OVERVIEW 142
12.2 ADULT 145
12.3 PEDIATRIC 145
12.4 GERIATRIC 146

13 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP 147

13.1 OVERVIEW 148
13.2 20-50 YEARS 151
13.3 LESS THAN 20 YEARS 152
13.4 ABOVE 50 YEARS 153

14 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL 154

14.1 OVERVIEW 155
14.2 B2B 158
14.3 B2C 158

15 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY REGION 159

15.1 MIDDLE EAST AND AFRICA 162
- 15.1.1 SAUDI ARABIA 170
- 15.1.2 EGYPT 176
- 15.1.3 SOUTH AFRICA 182
- 15.1.4 KUWAIT 187
- 15.1.5 U.A.E. 192
- 15.1.6 ISRAEL 198
- 15.1.7 REST OF MIDDLE EAST AND AFRICA 203

16 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: COMPANY LANDSCAPE 204

16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

17 SWOT ANALYSIS 205

18 COMPANY PROFILE 206

18.1 PFIZER INC. 206
- 18.1.1 COMPANY SNAPSHOT 206
- 18.1.2 REVENUE ANALYSIS 206
- 18.1.3 COMPANY SHARE ANALYSIS 207
- 18.1.4 PRODUCT PORTFOLIO 207
- 18.1.5 RECENT DEVELOPMENT 208
18.2 SANOFI 209
- 18.2.1 COMPANY SNAPSHOT 209
- 18.2.2 REVENUE ANALYSIS 209
- 18.2.3 COMPANY SHARE ANALYSIS 210
- 18.2.4 PRODUCT PORTFOLIO 210
- 18.2.5 RECENT DEVELOPMENT 214
18.3 JOHNSON & JOHNSON SERVICES INC. 215
- 18.3.1 COMPANY SNAPSHOT 215
- 18.3.2 REVENUE ANALYSIS 215
- 18.3.3 COMPANY SHARE ANALYSIS 216
- 18.3.4 PRODUCT PORTFOLIO 216
- 18.3.5 RECENT DEVELOPMENTS 217
18.4 GSK PLC. 218
- 18.4.1 COMPANY SNAPSHOT 218
- 18.4.2 REVENUE ANALYSIS 218
- 18.4.3 COMPANY SHARE ANALYSIS 219
- 18.4.4 PRODUCT PORTFOLIO 219
- 18.4.5 RECENT DEVELOPMENT 224
18.5 MERCK & CO., INC. 226
- 18.5.1 COMPANY SNAPSHOT 226
- 18.5.2 REVENUE ANALYSIS 226
- 18.5.3 COMPANY SHARE ANALYSIS 227
- 18.5.4 PRODUCT PORTFOLIO 227
- 18.5.5 RECENT DEVELOPMENT 229
18.6 ABBOTT 230
- 18.6.1 COMPANY SNAPSHOT 230
- 18.6.2 REVENUE ANALYSIS 230
- 18.6.3 PRODUCT PORTFOLIO 231
- 18.6.4 RECENT DEVELOPMENT 232
18.7 ASTRAZENECA 233
- 18.7.1 COMPANY SNAPSHOT 233
- 18.7.2 REVENUE ANALYSIS 233
- 18.7.3 PRODUCT PORTFOLIO 234
- 18.7.4 RECENT DEVELOPMENT 234
18.8 BAVARIAN NORDIC 236
- 18.8.1 COMPANY SNAPSHOT 236
- 18.8.2 REVENUE ANALYSIS 236
- 18.8.3 PRODUCT PORTFOLIO 237
- 18.8.4 RECENT DEVELOPMENT 237
18.9 CSL 239
- 18.9.1 COMPANY SNAPSHOT 239
- 18.9.2 REVENUE ANALYSIS 239
- 18.9.3 PRODUCT PORTFOLIO 240
- 18.9.4 RECENT DEVELOPMENT 241
18.10 DYNAVAX TECHNOLOGIES. 242
- 18.10.1 COMPANY SNAPSHOT 242
- 18.10.2 REVENUE ANALYSIS 242
- 18.10.3 PRODUCT PORTFOLIO 243
- 18.10.4 RECENT DEVELOPMENTS 243
18.11 VALNEVA SE 244
- 18.11.1 COMPANY SNAPSHOT 244
- 18.11.2 REVENUE ANALYSIS 244
- 18.11.3 PRODUCT PORTFOLIO 245
- 18.11.4 RECENT DEVELOPMENT 245

19 QUESTIONNAIRE 246

20 RELATED REPORTS 250

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS OF TRAVEL VACCINES MARKET 45
TABLE 2 VACCINES RECOMMENDATION FOR INTERNATIONAL TRAVELERS 51
TABLE 3 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 63
TABLE 4 MIDDLE EAST AND AFRICA COMBINATION VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 64
TABLE 5 MIDDLE EAST AND AFRICA MONO VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 64
TABLE 6 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 68
TABLE 7 MIDDLE EAST AND AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 69
TABLE 8 MIDDLE EAST AND AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 70
TABLE 9 MIDDLE EAST AND AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 71
TABLE 10 MIDDLE EAST AND AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 72
TABLE 11 MIDDLE EAST AND AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 73
TABLE 12 MIDDLE EAST AND AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 74
TABLE 13 MIDDLE EAST AND AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 75
TABLE 14 MIDDLE EAST AND AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 76
TABLE 15 MIDDLE EAST AND AFRICA DNA VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 76
TABLE 16 MIDDLE EAST AND AFRICA VIRAL VECTOR VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 77
TABLE 17 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 81
TABLE 18 MIDDLE EAST AND AFRICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 82
TABLE 19 MIDDLE EAST AND AFRICA RECOMMENDED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 82
TABLE 20 MIDDLE EAST AND AFRICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 84
TABLE 21 MIDDLE EAST AND AFRICA ROUTINE VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 84
TABLE 22 MIDDLE EAST AND AFRICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 86
TABLE 23 MIDDLE EAST AND AFRICA REQUIRED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 86
TABLE 24 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 92
TABLE 25 MIDDLE EAST AND AFRICA TYPHOID IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 93
TABLE 26 MIDDLE EAST AND AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 93
TABLE 27 MIDDLE EAST AND AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 94
TABLE 28 MIDDLE EAST AND AFRICA CHOLERA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 94
TABLE 29 MIDDLE EAST AND AFRICA VARICELLA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 95
TABLE 30 MIDDLE EAST AND AFRICA INFLUENZA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 95
TABLE 31 MIDDLE EAST AND AFRICA JAPANESE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 96
TABLE 32 MIDDLE EAST AND AFRICA MENINGOCOCCAL MENINGITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 96
TABLE 33 MIDDLE EAST AND AFRICA YELLOW FEVER IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 97
TABLE 34 MIDDLE EAST AND AFRICA RABIES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 97
TABLE 35 MIDDLE EAST AND AFRICA DPT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 98
TABLE 36 MIDDLE EAST AND AFRICA MEASLES AND MUMPS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 98
TABLE 37 MIDDLE EAST AND AFRICA TICK-BORNE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 99
TABLE 38 MIDDLE EAST AND AFRICA MALARIA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 99
TABLE 39 MIDDLE EAST AND AFRICA COVID-19 IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 100
TABLE 40 MIDDLE EAST AND AFRICA POLIO IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 100
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 101
TABLE 42 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 105
TABLE 43 MIDDLE EAST AND AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 106
TABLE 44 MIDDLE EAST AND AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 106
TABLE 45 MIDDLE EAST AND AFRICA ORAL IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 107
TABLE 46 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 111
TABLE 47 MIDDLE EAST AND AFRICA MALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 112
TABLE 48 MIDDLE EAST AND AFRICA FEMALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 112
TABLE 49 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 116
TABLE 50 MIDDLE EAST AND AFRICA ADULT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 117
TABLE 51 MIDDLE EAST AND AFRICA PEDIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 117
TABLE 52 MIDDLE EAST AND AFRICA GERIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 118
TABLE 53 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 122
TABLE 54 MIDDLE EAST AND AFRICA 20-50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 123
TABLE 55 MIDDLE EAST AND AFRICA LESS THAN 20 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 124
TABLE 56 MIDDLE EAST AND AFRICA ABOVE 50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 125
TABLE 57 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 129
TABLE 58 MIDDLE EAST AND AFRICA B2B IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 130
TABLE 59 MIDDLE EAST AND AFRICA B2C IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND) 130
TABLE 60 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND) 134
TABLE 61 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 134
TABLE 62 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 135
TABLE 63 MIDDLE EAST AND AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 135
TABLE 64 MIDDLE EAST AND AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 136
TABLE 65 MIDDLE EAST AND AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 136
TABLE 66 MIDDLE EAST AND AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 136
TABLE 67 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 137
TABLE 68 MIDDLE EAST AND AFRICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 137
TABLE 69 MIDDLE EAST AND AFRICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 138
TABLE 70 MIDDLE EAST AND AFRICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 138
TABLE 71 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 139
TABLE 72 MIDDLE EAST AND AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 139
TABLE 73 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 139
TABLE 74 MIDDLE EAST AND AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 140
TABLE 75 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 140
TABLE 76 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 140
TABLE 77 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 141
TABLE 78 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 141
TABLE 79 SAUDI ARABIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 142
TABLE 80 SAUDI ARABIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 142
TABLE 81 SAUDI ARABIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 142
TABLE 82 SAUDI ARABIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 143
TABLE 83 SAUDI ARABIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 143
TABLE 84 SAUDI ARABIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 143
TABLE 85 SAUDI ARABIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 144
TABLE 86 SAUDI ARABIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 144
TABLE 87 SAUDI ARABIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 144
TABLE 88 SAUDI ARABIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 145
TABLE 89 SAUDI ARABIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 145
TABLE 90 SAUDI ARABIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 145
TABLE 91 SAUDI ARABIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 146
TABLE 92 SAUDI ARABIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 146
TABLE 93 SAUDI ARABIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 146
TABLE 94 SAUDI ARABIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 146
TABLE 95 SAUDI ARABIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 147
TABLE 96 SAUDI ARABIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 147
TABLE 97 EGYPT TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 148
TABLE 98 EGYPT TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 148
TABLE 99 EGYPT INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 148
TABLE 100 EGYPT SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 149
TABLE 101 EGYPT LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 149
TABLE 102 EGYPT TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 149
TABLE 103 EGYPT TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 149
TABLE 104 EGYPT RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 150
TABLE 105 EGYPT ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 150
TABLE 106 EGYPT REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 150
TABLE 107 EGYPT TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 151
TABLE 108 EGYPT HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 151
TABLE 109 EGYPT TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 151
TABLE 110 EGYPT INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 152
TABLE 111 EGYPT TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 152
TABLE 112 EGYPT TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 152
TABLE 113 EGYPT TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 152
TABLE 114 EGYPT TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 153
TABLE 115 SOUTH AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 154
TABLE 116 SOUTH AFRICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 154
TABLE 117 SOUTH AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 154
TABLE 118 SOUTH AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 155
TABLE 119 SOUTH AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 155
TABLE 120 SOUTH AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 155
TABLE 121 SOUTH AFRICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 155
TABLE 122 SOUTH AFRICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 156
TABLE 123 SOUTH AFRICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 156
TABLE 124 SOUTH AFRICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 156
TABLE 125 SOUTH AFRICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 157
TABLE 126 SOUTH AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 157
TABLE 127 SOUTH AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 157
TABLE 128 SOUTH AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 158
TABLE 129 SOUTH AFRICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 158
TABLE 130 SOUTH AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 158
TABLE 131 SOUTH AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 158
TABLE 132 SOUTH AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 158
TABLE 133 KUWAIT TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 159
TABLE 134 KUWAIT TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 159
TABLE 135 KUWAIT INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 159
TABLE 136 KUWAIT SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 160
TABLE 137 KUWAIT LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 160
TABLE 138 KUWAIT TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 160
TABLE 139 KUWAIT TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 160
TABLE 140 KUWAIT RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 161
TABLE 141 KUWAIT ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 161
TABLE 142 KUWAIT REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 161
TABLE 143 KUWAIT TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 162
TABLE 144 KUWAIT HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 162
TABLE 145 KUWAIT TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 162
TABLE 146 KUWAIT INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 163
TABLE 147 KUWAIT TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 163
TABLE 148 KUWAIT TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 163
TABLE 149 KUWAIT TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 163
TABLE 150 KUWAIT TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 163
TABLE 151 U.A.E. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 164
TABLE 152 U.A.E. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 164
TABLE 153 U.A.E. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 164
TABLE 154 U.A.E. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 165
TABLE 155 U.A.E. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 165
TABLE 156 U.A.E. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 165
TABLE 157 U.A.E. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 166
TABLE 158 U.A.E. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 166
TABLE 159 U.A.E. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 166
TABLE 160 U.A.E. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 167
TABLE 161 U.A.E. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 167
TABLE 162 U.A.E. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 167
TABLE 163 U.A.E. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 168
TABLE 164 U.A.E. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 168
TABLE 165 U.A.E. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 168
TABLE 166 U.A.E. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 168
TABLE 167 U.A.E. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 168
TABLE 168 U.A.E. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 169
TABLE 169 ISRAEL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 170
TABLE 170 ISRAEL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 170
TABLE 171 ISRAEL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 170
TABLE 172 ISRAEL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 171
TABLE 173 ISRAEL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 171
TABLE 174 ISRAEL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND) 171
TABLE 175 ISRAEL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 171
TABLE 176 ISRAEL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 172
TABLE 177 ISRAEL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 172
TABLE 178 ISRAEL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND) 172
TABLE 179 ISRAEL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 173
TABLE 180 ISRAEL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND) 173
TABLE 181 ISRAEL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 173
TABLE 182 ISRAEL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND) 174
TABLE 183 ISRAEL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND) 174
TABLE 184 ISRAEL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND) 174
TABLE 185 ISRAEL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND) 174
TABLE 186 ISRAEL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND) 174
TABLE 187 REST OF MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND) 175

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET: SEGMENTATION 26
FIGURE 2 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET: DATA TRIANGULATION 29
FIGURE 3 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET: DROC ANALYSIS 30
FIGURE 4 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET : MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS 31
FIGURE 5 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET : COMPANY RESEARCH ANALYSIS 31
FIGURE 6 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET: INTERVIEW DEMOGRAPHICS 33
FIGURE 7 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET: DBMR MARKET POSITION GRID 34
FIGURE 8 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET: MARKET APPLICATION COVERAGE GRID 35
FIGURE 9 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET: VENDOR SHARE ANALYSIS 36
FIGURE 10 MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET: SEGMENTATION 40
FIGURE 11 RISING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION AMONG TRAVELERS ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET IN THE FORECAST PERIOD OF 2024 TO 2032 41
FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA TRAVEL VACCINES MARKET IN 2021 & 2032 41
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET 49
FIGURE 14 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY COMPOSITION, 2023 60
FIGURE 15 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY COMPOSITION, 2024-2032 (USD THOUSAND) 61
FIGURE 16 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY COMPOSITION , CAGR (2024-2032) 61
FIGURE 17 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY COMPOSITION, LIFELINE CURVE 62
FIGURE 18 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY TYPE, 2023 65
FIGURE 19 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY TYPE, 2024-2032 (USD THOUSAND) 66
FIGURE 20 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY TYPE, CAGR (2024-2032) 66
FIGURE 21 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY TYPE, LIFELINE CURVE 67
FIGURE 22 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY CATEGORY, 2023 78
FIGURE 23 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY CATEGORY, 2024-2032 (USD THOUSAND) 79
FIGURE 24 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY CATEGORY, CAGR (2024-2032) 79
FIGURE 25 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY CATEGORY, LIFELINE CURVE 80
FIGURE 26 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY DISEASE, 2023 88
FIGURE 27 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY DISEASE, 2024-2032 (USD THOUSAND) 89
FIGURE 28 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY DISEASE, CAGR (2024-2032) 89
FIGURE 29 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY DISEASE, LIFELINE CURVE 90
FIGURE 30 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2023 102
FIGURE 31 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2032 (USD THOUSAND) 103
FIGURE 32 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2032) 103
FIGURE 33 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 104
FIGURE 34 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY GENDER, 2023 108
FIGURE 35 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY GENDER, 2024-2032 (USD THOUSAND) 109
FIGURE 36 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY GENDER, CAGR (2024-2032) 109
FIGURE 37 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY GENDER, LIFELINE CURVE 110
FIGURE 38 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2023 113
FIGURE 39 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2024-2032 (USD THOUSAND) 114
FIGURE 40 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY PATIENT TYPE, CAGR (2024-2032) 114
FIGURE 41 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY PATIENT TYPE, LIFELINE CURVE 115
FIGURE 42 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY AGE GROUP, 2023 119
FIGURE 43 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY AGE GROUP, 2024-2032 (USD THOUSAND) 120
FIGURE 44 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY AGE GROUP, CAGR (2024-2032) 120
FIGURE 45 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY AGE GROUP, LIFELINE CURVE 121
FIGURE 46 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2023 126
FIGURE 47 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2024-2032 (USD THOUSAND) 127
FIGURE 48 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2032) 127
FIGURE 49 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 128
FIGURE 50 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: SNAPSHOT (2023) 131
FIGURE 51 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%) 175